NCT03847350

Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension

An Observational Study to Identify BEnefits After 24 Weeks of NEBILET®(Nebivolol) Administration For Essential hypertensIon Patients With Various Co-morbidities and Treatment Environments in KOREA.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,250 (actual)
• Sponsor: A.Menarini Asia-Pacific Holdings Pte Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: —

Summary

The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.

Detailed description

Nebivolol, the third-generation beta-blocker with vasodilatory effect, potentiates nitric oxide by activating the synthesis of nitric oxide of vascular endothelial cells and improves the function of vascular endothelial cells by reducing oxidation stress. The efficacy of NEBILET®(Nebivolol) has been demonstrated in randomized controlled trials not only as monotherapy but also as add-on therapy with angiotensin-converting-enzyme inhibitor, angiotensin II receptor blocker, diuretic and other anti-hypertensive agents in lowering the blood pressure. Based on previous study results mentioned above, the present study aims to observe the effect of NEBILET®(Nebivolol) on controlling blood pressure and metabolic profile change in Korean patients with hypertension under routine clinical practice. In addition, this study aims to identify additional benefits of NEBILET®(Nebivolol) administration in patients with essential hypertension under various treatment environments and existing co-morbidities in Korea, expected to provide detailed information about efficacy of blood pressure control, lipid and carbohydrate metabolism of NEBILET®(Nebivolol) administration in Korean patients with essential hypertension.

Conditions

• Essential Hypertension

Timeline

• Start date: 2015-07-01
• Primary completion: 2017-03-23
• Completion: 2017-03-23
• First posted: 2019-02-20
• Last updated: 2019-02-20

Locations

1 site across 1 country: South Korea